Thursday, July 23, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
283
Patents
1436
Clinical program

pantoprazole 20 mg (drug)

Phase 3 · small molecule · Chronic Use of Acid Suppressive Medication

pantoprazole 20 mg (drug) for Chronic Use of Acid Suppressive Medication is a Phase 3 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 3 small molecule active

Internal code BY1023/NL503

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 3
Modality
small_molecule
Indication
Chronic Use of Acid Suppressive Medication
Status
active
Trials
1